Digital symptom management is shown to improve patients’ overall survival and quality of life.

Cancer immunotherapies
Modules for managing immune-related adverse events
There’s still limited knowledge on adverse events when treating patients with cancer immunotherapies. These adverse events may include the body’s own immune system attacking healthy tissues. We are actively working with leading centers in order to better understand and manage toxicities of Immune Checkpoint Inhibitor and CAR T Cell therapies.
Scientific evidence
Impact of digital patient monitoring
Overall survival
Studies show increased overall survival with patient-reported symptom monitoring compared to usual care.
A randomised controlled trial with 766 metastatic cancer patients shows that digital symptom monitoring during chemotherapy helps patients live longer (5.2 months longer median overall survival), improves quality of life (31% of patients), and reduces hospitalisation (4%) and ER visits (7%). (Basch & al. 2016–2017).
PRO-monitoring vs. usual care
Patients' quality of life after 6 months
ER visits and hospitalization at one year mark
(P=0.02)
(P=0.08)
Duration that patients remained in chemotherapy
(P=0.02)
We are actively contributing to unveiling the value of digital symptom management and Patient-Reported Outcomes in routine cancer care.
Applications
Kaiku Health is used for capturing and processing data in all common cancer types
Breast cancer
Prostate and other urological cancers
Lung cancer
Colorectal and other GI cancers
Hematologic cancers
Melanoma and other skin cancers
Gynecological cancers
Head and neck cancers
Compliant with all cancer care pathways
- Surgery
- Systemic therapies
- Radiotherapy
- Follow-up
- Palliative care